With the coming release of an innovative screw system for spinal surgeons, Baxano Surgical Inc (NASDAQ: BAXS) is hoping to improve lagging sales for its product line. Recent revenue reports have not been nice to BAXS as its stock has dropped to a 5-year low.
The recent FDA clearance for the Avance™ MIS Pedicle Screw System comes at a good time for Baxano Surgical as they look to bolster their 8-figure sales in the medical device industry. Many research and analyst firms are talking target prices ranging from $1.40 to $2.50 per share in the short term so we’ve got BAXS on our radar.
http://finance.yahoo.com/q?s=BAXS
The post Baxano Surgical Inc (BAXS) Stock Watch appeared first on TKO Stocks.
